XML 55 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' Equity (Tables)
 12 Months Ended
Jun. 30, 2022
Stockholders' Equity Note [Abstract]  
Schedule Of Activity Of Restricted Stock Units
The following table summarizes the activity of RSUs, including PRSUs, during year ended June 30, 2022 (in thousands, except years and per share amounts):
Restricted
Stock
Units		Weighted
Average
Grant-Date
Fair Value		Weighted
Average
Remaining
Contractual
Term in Years
Outstanding at beginning of period875 $145.19 1.5
Granted288 259.46 
Vested*(575)113.85 
Performance factor adjustment175 — 
Forfeited (82)184.30 
Outstanding at end of period681 $203.46 1.6
*Includes 206 thousand shares netted for tax.
Schedule Of Option Activity
The following table summarizes option activity during the year ended June 30, 2022 (in thousands, except years and per share amounts):
OptionsWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Term in Years
Outstanding at beginning of period1,060 $97.01 3.7
Granted56 256.33 
Exercised(177)63.31 
Forfeited(1)110.19 
Outstanding at end of period938 $112.91 3.2
Options exercisable at end of period792 $96.14 2.8
Options vested and expected to vest at end of period932 $112.10 3.2
Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted
We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June 30, 2022, 2021 and 2020:
202220212020
Stock options:
Weighted average grant date fair value$72.16$53.67$32.14
Weighted average risk-free interest rate1.29%0.37%1.58%
Expected life in years4.94.94.9
Dividend yield0.66%0.75%1.07%
Expected volatility32%31%25%
ESPP purchase rights:
Weighted average grant date fair value$50.46$48.18$31.82
Weighted average risk-free interest rate0.3%0.1%1.6%
Expected life in years6 months6 months6 months
Dividend yield
0.63% - 0.98%
0.79% - 0.98%
0.98% - 1.42%
Expected volatility
20% - 34%
30% - 60%
23% - 60%
Schedule Of Total Stock-Based Compensation Costs Incurred And Associated Tax Benefit Recognized
The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June 30, 2022, 2021 and 2020 (in thousands):
202220212020
Cost of sales $5,218 $4,153 $3,703 
Selling, general and administrative expenses50,791 51,727 47,265 
Research and development expenses9,248 8,047 6,591 
Stock-based compensation costs65,257 63,927 57,559 
Tax benefit(29,262)(23,346)(39,534)
Stock-based compensation costs, net of tax benefit$35,995 $40,581 $18,025